Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39787   clinical trials with a EudraCT protocol, of which   6529   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

    Summary
    EudraCT number
    2011-003142-41
    Trial protocol
    IT   LT   FI   PL   BE   CZ   ES   EE   GR   DE   GB   SE   AT   DK   LV   NO   NL   HU   IE   SK   BG  
    Global end of trial date
    29 Jun 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    15 Jul 2018
    First version publication date
    15 Jul 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    20110142
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01631214
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Amgen Inc.
    Sponsor organisation address
    One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
    Public contact
    IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
    Scientific contact
    IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Jun 2017
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Jun 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective was to assess the effect of romosozumab treatment for 12 months followed by alendronate treatment compared with alendronate treatment alone on the subject incidence of: - clinical fracture (nonvertebral fracture and clinical vertebral fracture); and - new vertebral fracture in postmenopausal women with osteoporosis.
    Protection of trial subjects
    This study was conducted in accordance with International Council on Harmonisation (ICH) Good Clinical Practice (GCP) and applicable Food and Drug Administration (FDA) or local regulations/guidelines. The study protocol, subject information, and informed consent form (ICF) were reviewed and approved by the independent ethics committee (IEC) or institutional review board (IRB) for each study center. Before any study procedures were performed or any investigational products were administered, the investigator obtained written informed consent from each subject after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    04 May 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Slovakia: 16
    Country: Number of subjects enrolled
    South Africa: 154
    Country: Number of subjects enrolled
    Spain: 38
    Country: Number of subjects enrolled
    Sweden: 28
    Country: Number of subjects enrolled
    Taiwan: 6
    Country: Number of subjects enrolled
    Turkey: 9
    Country: Number of subjects enrolled
    United Kingdom: 76
    Country: Number of subjects enrolled
    United States: 57
    Country: Number of subjects enrolled
    Argentina: 108
    Country: Number of subjects enrolled
    Australia: 19
    Country: Number of subjects enrolled
    Austria: 37
    Country: Number of subjects enrolled
    Belgium: 29
    Country: Number of subjects enrolled
    Brazil: 295
    Country: Number of subjects enrolled
    Bulgaria: 112
    Country: Number of subjects enrolled
    Canada: 40
    Country: Number of subjects enrolled
    Chile: 24
    Country: Number of subjects enrolled
    Colombia: 634
    Country: Number of subjects enrolled
    Czech Republic: 282
    Country: Number of subjects enrolled
    Denmark: 73
    Country: Number of subjects enrolled
    Dominican Republic: 29
    Country: Number of subjects enrolled
    Estonia: 51
    Country: Number of subjects enrolled
    Finland: 13
    Country: Number of subjects enrolled
    France: 41
    Country: Number of subjects enrolled
    Germany: 38
    Country: Number of subjects enrolled
    Greece: 33
    Country: Number of subjects enrolled
    Guatemala: 75
    Country: Number of subjects enrolled
    Hong Kong: 249
    Country: Number of subjects enrolled
    Hungary: 142
    Country: Number of subjects enrolled
    Israel: 7
    Country: Number of subjects enrolled
    Italy: 76
    Country: Number of subjects enrolled
    Korea, Republic of: 20
    Country: Number of subjects enrolled
    Latvia: 43
    Country: Number of subjects enrolled
    Lithuania: 50
    Country: Number of subjects enrolled
    Mexico: 117
    Country: Number of subjects enrolled
    Netherlands: 25
    Country: Number of subjects enrolled
    New Zealand: 9
    Country: Number of subjects enrolled
    Norway: 35
    Country: Number of subjects enrolled
    Peru: 119
    Country: Number of subjects enrolled
    Poland: 704
    Country: Number of subjects enrolled
    Romania: 23
    Country: Number of subjects enrolled
    Russian Federation: 157
    Worldwide total number of subjects
    4093
    EEA total number of subjects
    1965
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    479
    From 65 to 84 years
    3286
    85 years and over
    328

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 270 centers in 41 countries globally from 04 May 2012 to 29 June 2017.

    Pre-assignment
    Screening details
    Participants were randomized in a 1:1 ratio to receive romosozumab or alendronate for 12 months. Randomization was stratified by age (< 75 vs. ≥ 75 years). After completion of the double-blind trial period, all participants received open-label alendronate until the end of the trial, with blinding to the initial treatment assignment maintained.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Assessor, Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Alendronate/Alendronate
    Arm description
    Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
    Arm type
    Active comparator

    Investigational medicinal product name
    Alendronate
    Investigational medicinal product code
    Other name
    Fosamax®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Alendronate 70-mg tablet taken once a week

    Investigational medicinal product name
    Placebo to Romosozumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Administered by subcutaneous injection once a month during the double-blind treatment phase.

    Arm title
    Romosozumab/Alendronate
    Arm description
    Participants received 210 romosozumab mg subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo to Alendronate
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Matching placebo tablet taken once a week during the double-blind treatment phase.

    Investigational medicinal product name
    Alendronate
    Investigational medicinal product code
    Other name
    Fosamax®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Alendronate 70 mg tablet taken once a week during the open-label treatment phase.

    Investigational medicinal product name
    Romosozumab
    Investigational medicinal product code
    AMG 785
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.

    Number of subjects in period 1
    Alendronate/Alendronate Romosozumab/Alendronate
    Started
    2047
    2046
    Received Double-blind Treatment
    2040
    2038
    Completed Double-blind Period
    1823
    1831
    Completed
    1503
    1523
    Not completed
    544
    523
         Death
    113
    106
         Other
    22
    19
         Requirement for alternative therapy
    8
    3
         Noncompliance
    16
    15
         Administrative decision
    1
    -
         Ineligibility determined
    5
    2
         Adverse event, non-fatal
    45
    45
         Consent withdrawn by subject
    276
    290
         Protocol deviation
    4
    3
         Lost to follow-up
    54
    40

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Alendronate/Alendronate
    Reporting group description
    Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.

    Reporting group title
    Romosozumab/Alendronate
    Reporting group description
    Participants received 210 romosozumab mg subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.

    Reporting group values
    Alendronate/Alendronate Romosozumab/Alendronate Total
    Number of subjects
    2047 2046 4093
    Age Categorical
    Units: Subjects
        Adults (18-64 years)
    240 239 479
        From 65-84 years
    1642 1644 3286
        85 years and over
    165 163 328
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    74.2 ± 7.5 74.4 ± 7.5 -
    Gender Categorical
    Units: Subjects
        Female
    2047 2046 4093
        Male
    0 0 0
    Race
    Units: Subjects
        American Indian or Alaska Native
    7 5 12
        Asian
    149 137 286
        Black or African American
    23 19 42
        Native Hawaiian or Other Pacific Islander
    2 0 2
        White
    1415 1447 2862
        Multiple
    4 2 6
        Other
    446 436 882
        Missing
    1 0 1
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    662 631 1293
        Not Hispanic or Latino
    1385 1415 2800
    Age Strata per Randomization
    Units: Subjects
        < 75 years
    976 973 1949
        ≥ 75 years
    1071 1073 2144
    Severe Vertebral Fracture
    A subject had a prevalent vertebral fracture if any vertebra from T4 to L4 had a grade of 3 at baseline based on an assessment of spinal radiographs using Genant Semiquantitative Scoring Method. Otherwise, a subject was considered absence of severe vertebral fracture at baseline. vertebral fracture at baseline.
    Units: Subjects
        Presence
    1321 1369 2690
        Absence
    726 677 1403
    Total Hip Bone Mineral Density (BMD) T-score
    BMD was measured using dual-energy x-ray absorptiometry (DXA). The T-score is a comparison of a person's bone density with that of a healthy 30-year-old of the same sex. Lower scores (more negative) mean lower bone density: A T-score of -2.5 or lower qualifies as osteoporosis and a T-score of -1.0 to -2.5 signifies osteopenia, meaning below-normal bone density without full osteoporosis.
    Units: Subjects
        ≤ -2.5
    1384 1356 2740
        > -2.5
    662 690 1352
        Missing
    1 0 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Alendronate/Alendronate
    Reporting group description
    Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.

    Reporting group title
    Romosozumab/Alendronate
    Reporting group description
    Participants received 210 romosozumab mg subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.

    Primary: Percentage of Participants with New Vertebral Fractures Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with New Vertebral Fractures Through Month 24
    End point description
    New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method based on assessment of x-rays according to the following scale: • Grade 0 (Normal) = no fracture; • Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); • Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; • Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. The analysis was conducted in randomized participants with a baseline and ≥ 1 post-baseline evaluation of vertebral fracture at or before 24 months and includes participants who had vertebrae with missing Genant semiquantitative scores at baseline and whose first post-baseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.
    End point type
    Primary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1834
    1825
    Units: percentage of participants
        number (not applicable)
    8.0
    4.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority [1]
    P-value
    < 0.001 [2]
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    0.48
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.36
         upper limit
    0.64
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.15
    Notes
    [1] - The primary endpoints were tested at the 5% level (2-sided), accounting for multiplicity using the Hochberg procedure. If the larger of the 2 P-values was significant at the 0.05 level (2-sided), the statistical testing continued to the secondary endpoint in the testing sequence.
    [2] - Based on logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline. The standard error (SE) represents the standard error of log(odds ratio).
    Statistical analysis title
    Risk Ratio
    Statistical analysis description
    The risk ratio (ratio of proportions, Romosozumab over Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (<75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T score at the total hip (≤ -2.5, > -2.5). SE represents the standard error of log(risk ratio).
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Risk ratio (RR)
    Point estimate
    0.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.38
         upper limit
    0.66
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.14
    Statistical analysis title
    Absolute Risk Reduction
    Statistical analysis description
    The absolute risk reduction (difference in proportions, alendronate – romosozumab) based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, > -2.5), and presence of severe vertebral fracture at baseline.
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Absolute risk reduction
    Point estimate
    4.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.5
         upper limit
    5.57
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.78

    Primary: Percentage of Participants with a Clinical Fracture at the Primary Analysis

    Close Top of page
    End point title
    Percentage of Participants with a Clinical Fracture at the Primary Analysis
    End point description
    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants. Missing values for clinical vertebral fractures were imputed using last observation carried forward.
    End point type
    Primary
    End point timeframe
    The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    13.0
    9.7
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [3]
    P-value
    < 0.001 [4]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.61
         upper limit
    0.88
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.09
    Notes
    [3] - The primary endpoints were tested at the 5% level (2-sided), accounting for multiplicity using the Hochberg procedure. If the larger of the 2 P-values was significant at the 0.05 level (2-sided), the statistical testing continued to the secondary endpoint in the testing sequence.
    [4] - Based on a Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Nonvertebral Fracture at the Primary Analysis

    Close Top of page
    End point title
    Percentage of Participants with a Nonvertebral Fracture at the Primary Analysis
    End point description
    A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    10.6
    8.7
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [5]
    P-value
    = 0.04 [6]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.81
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.66
         upper limit
    0.99
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.1
    Notes
    [5] - If the 2 primary endpoints and the specified BMD secondary endpoints were all significant, the nonvertebral fracture at the primary analysis was evaluated based on a 1-sided test (overall α=0.025) determined by the Lan-DeMets alpha spending function that approximates a Pocock boundary, 0.0233 (1-sided). The adjusted 2-sided p-value is reported.
    [6] - Based on a Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with any Fracture at the Primary Analysis

    Close Top of page
    End point title
    Percentage of Participants with any Fracture at the Primary Analysis
    End point description
    All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    19.1
    13.0
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [7]
    P-value
    < 0.001 [8]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.65
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.56
         upper limit
    0.76
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.08
    Notes
    [7] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [8] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a New or Worsening Vertebral Fracture Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with a New or Worsening Vertebral Fracture Through Month 24
    End point description
    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. The analysis was conducted in randomized participants with a baseline and ≥ 1 post-baseline evaluation of vertebral fracture at or before 24 months and includes participants who had vertebrae with missing Genant semiquantitative scores at baseline and whose first post-baseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1834
    1825
    Units: percentage of participants
        number (not applicable)
    9.2
    4.8
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority [9]
    P-value
    < 0.001 [10]
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    0.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.37
         upper limit
    0.64
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.14
    Notes
    [9] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [10] - Based on a logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline; p-value based on score test. SE represents the standard error of log(odds ratio).
    Statistical analysis title
    Absolute Risk Reduction
    Statistical analysis description
    The absolute risk reduction (difference in proportions, Alendronate – Romosozumab) based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, > -2.5), and presence of severe vertebral fracture at baseline.
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Absolute Risk Reduction
    Point estimate
    4.44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.8
         upper limit
    6.08
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.84
    Statistical analysis title
    Risk Ratio
    Statistical analysis description
    The risk ratio (ratio of proportions, Romosozumab over Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (<75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T score at the total hip (≤ -2.5, > -2.5). SE represents the standard error of log(risk ratio).
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Risk ratio (RR)
    Point estimate
    0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.4
         upper limit
    0.66
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.13

    Secondary: Percentage of Participants with a Major Nonvertebral Fracture at the Primary Analysis

    Close Top of page
    End point title
    Percentage of Participants with a Major Nonvertebral Fracture at the Primary Analysis
    End point description
    A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    9.6
    7.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [11]
    P-value
    = 0.004 [12]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.59
         upper limit
    0.9
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.11
    Notes
    [11] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [12] - Based on a Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Hip Fracture at the Primary Analysis

    Close Top of page
    End point title
    Percentage of Participants with a Hip Fracture at the Primary Analysis
    End point description
    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    3.2
    2.0
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [13]
    P-value
    = 0.015 [14]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.62
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.42
         upper limit
    0.92
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [13] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [14] - Based on a Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with Multiple New or Worsening Vertebral Fractures Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with Multiple New or Worsening Vertebral Fractures Through Month 24
    End point description
    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. The analysis was conducted in randomized participants with a baseline and ≥ 1 post-baseline evaluation of vertebral fracture at or before 24 months and includes participants who had vertebrae with missing Genant semiquantitative scores at baseline and whose first post-baseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1834
    1825
    Units: percentage of participants
        number (not applicable)
    2.5
    1.3
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority [15]
    P-value
    = 0.008 [16]
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    0.51
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.31
         upper limit
    0.85
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.25
    Notes
    [15] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [16] - Based on logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline. SE represents the standard error of log(odds ratio).
    Statistical analysis title
    Risk Ratio
    Statistical analysis description
    The risk ratio (ratio of proportions, Romosozumab over Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (<75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T score at the total hip (≤ -2.5, > -2.5). SE represents the standard error of log(risk ratio).
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Risk ratio (RR)
    Point estimate
    0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.32
         upper limit
    0.85
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.25
    Statistical analysis title
    Absolute Risk Reduction
    Statistical analysis description
    The absolute risk reduction (difference in proportions, alendronate – romosozumab) based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, > -2.5), and presence of severe vertebral fracture at baseline.
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3659
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Absolute risk reduction
    Point estimate
    1.21
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.33
         upper limit
    2.1
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.45

    Secondary: Percentage of Participants with a Clinical Fracture Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with a Clinical Fracture Through Month 24
    End point description
    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants. Missing values for clinical vertebral fractures were imputed using last observation carried forward.
    End point type
    Secondary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    9.6
    7.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [17]
    P-value
    = 0.005 [18]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.74
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.59
         upper limit
    0.91
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.11
    Notes
    [17] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [18] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Nonvertebral Fracture Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with a Nonvertebral Fracture Through Month 24
    End point description
    A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    7.8
    6.3
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [19]
    P-value
    = 0.074 [20]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.81
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.64
         upper limit
    1.02
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.12
    Notes
    [19] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [20] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Hip Fracture Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with a Hip Fracture Through Month 24
    End point description
    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    2.1
    1.5
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [21]
    P-value
    = 0.17 [22]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.72
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.46
         upper limit
    1.15
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.24
    Notes
    [21] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [22] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Clinical Vertebral Fracture Through Month 24

    Close Top of page
    End point title
    Percentage of Participants with a Clinical Vertebral Fracture Through Month 24
    End point description
    A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. The analysis was conducted in all randomized participants. Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    24 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    2.1
    0.9
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [23]
    P-value
    < 0.001 [24]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.41
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.24
         upper limit
    0.71
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.28
    Notes
    [23] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [24] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log(hazards ratio).

    Secondary: Percentage of Participants with a Clinical Fracture Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with a Clinical Fracture Through Month 12
    End point description
    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants. Missing values for clinical vertebral fractures were imputed using last observation carried forward.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    5.4
    3.9
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [25]
    P-value
    = 0.027 [26]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.72
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.54
         upper limit
    0.96
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.15
    Notes
    [25] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [26] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with New Vertebral Fractures Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with New Vertebral Fractures Through Month 12
    End point description
    New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method based on assessment of x-rays according to the following scale: • Grade 0 (Normal) = no fracture; • Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); • Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; • Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. The analysis was conducted in randomized participants with a baseline and ≥ 1 post-baseline evaluation of vertebral fracture at or before 12 months and includes participants who had vertebrae with missing Genant semiquantitative scores at baseline and whose first post-baseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1703
    1696
    Units: percentage of participants
        number (not applicable)
    5.0
    3.2
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3399
    Analysis specification
    Pre-specified
    Analysis type
    superiority [27]
    P-value
    = 0.008 [28]
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    0.63
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.44
         upper limit
    0.89
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.18
    Notes
    [27] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [28] - Based on logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline. SE represents the standard error of log (odds ratio).
    Statistical analysis title
    Risk Ratio
    Statistical analysis description
    The risk ratio (ratio of proportions, Romosozumab over Alendronate) was based on the Mantel Haenszel method, adjusted for age strata (<75 vs. ≥75 years), the presence or absence of severe vertebral fracture at baseline, and baseline bone mineral density T score at the total hip (≤ -2.5, > -2.5). SE represents the standard error of log (risk ratio).
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3399
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Risk ratio (RR)
    Point estimate
    0.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.46
         upper limit
    0.89
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.17
    Statistical analysis title
    Absolute Risk Reduction
    Statistical analysis description
    The absolute risk reduction (difference in proportions, alendronate – romosozumab) based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score (≤ -2.5, > -2.5), and presence of severe vertebral fracture at baseline.
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3399
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Absolute risk reduction
    Point estimate
    1.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.51
         upper limit
    3.17
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.68

    Secondary: Percentage of Participants with Any Fracture Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with Any Fracture Through Month 12
    End point description
    All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    9.2
    6.5
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [29]
    P-value
    = 0.002 [30]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.71
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.57
         upper limit
    0.88
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.11
    Notes
    [29] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [30] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Nonvertebral Fracture Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with a Nonvertebral Fracture Through Month 12
    End point description
    A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    4.6
    3.4
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [31]
    P-value
    = 0.057 [32]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.74
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.54
         upper limit
    1.01
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.16
    Notes
    [31] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [32] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Hip Fracture Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with a Hip Fracture Through Month 12
    End point description
    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    1.1
    0.7
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [33]
    P-value
    = 0.19 [34]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.33
         upper limit
    1.26
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.34
    Notes
    [33] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [34] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Major Osteoporotic Fracture Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with a Major Osteoporotic Fracture Through Month 12
    End point description
    Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. The analysis was conducted in all randomized participants.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of particiapnts
        number (not applicable)
    4.2
    3.0
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    [35]
    P-value
    = 0.053 [36]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.72
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.52
         upper limit
    1.01
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.17
    Notes
    [35] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [36] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percentage of Participants with a Clinical Vertebral Fracture Through Month 12

    Close Top of page
    End point title
    Percentage of Participants with a Clinical Vertebral Fracture Through Month 12
    End point description
    A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. The analysis was conducted in all randomized participants. Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    12 months
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    2047
    2046
    Units: percentage of participants
        number (not applicable)
    0.9
    0.5
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    4093
    Analysis specification
    Pre-specified
    Analysis type
    superiority [37]
    P-value
    = 0.14 [38]
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.56
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.26
         upper limit
    1.22
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.39
    Notes
    [37] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [38] - Based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. SE represents the standard error of log (hazard ratio).

    Secondary: Percent Change from Baseline in Bone Mineral Density at the Lumbar Spine at Month 24

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density at the Lumbar Spine at Month 24
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.
    End point type
    Secondary
    End point timeframe
    Baseline and month 24
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1577
    1571
    Units: percent change
        least squares mean (standard error)
    7.2 ± 0.2
    15.3 ± 0.2
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3148
    Analysis specification
    Pre-specified
    Analysis type
    superiority [39]
    P-value
    < 0.001 [40]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    8.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    7.58
         upper limit
    8.57
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.3
    Notes
    [39] - If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.
    [40] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density of the Total Hip at Month 24

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density of the Total Hip at Month 24
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.
    End point type
    Secondary
    End point timeframe
    Baseline and month 24
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1627
    1622
    Units: percent change
        least squares mean (standard error)
    3.5 ± 0.1
    7.2 ± 0.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3249
    Analysis specification
    Pre-specified
    Analysis type
    superiority [41]
    P-value
    < 0.001 [42]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    3.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.42
         upper limit
    4.1
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [41] - If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.
    [42] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density of the Femoral Neck at Month 24

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density of the Femoral Neck at Month 24
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 24; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.
    End point type
    Secondary
    End point timeframe
    Baseline and month 24
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1627
    1622
    Units: percent change
        least squares mean (standard error)
    2.3 ± 0.2
    6.0 ± 0.2
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3249
    Analysis specification
    Pre-specified
    Analysis type
    superiority [43]
    P-value
    < 0.001 [44]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    3.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.4
         upper limit
    4.14
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [43] - If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.
    [44] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    Baseline and month 12
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1718
    1722
    Units: percent change
        least squares mean (standard error)
    5.0 ± 0.1
    13.7 ± 0.2
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3440
    Analysis specification
    Pre-specified
    Analysis type
    superiority [45]
    P-value
    < 0.001 [46]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    8.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    8.31
         upper limit
    9.09
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [45] - If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.
    [46] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density of the Total Hip at Month 12

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density of the Total Hip at Month 12
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    Baseline and month 12
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1781
    1781
    Units: percent change
        least squares mean (standard error)
    2.8 ± 0.1
    6.2 ± 0.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3562
    Analysis specification
    Pre-specified
    Analysis type
    superiority [47]
    P-value
    < 0.001 [48]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    3.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.03
         upper limit
    3.6
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.1
    Notes
    [47] - If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.
    [48] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density of the Femoral Neck at Month 12

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density of the Femoral Neck at Month 12
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation at or before month 12; Last observation carried forward imputation was used.
    End point type
    Secondary
    End point timeframe
    Baseline and month 12
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1781
    1781
    Units: percent change
        least squares mean (standard error)
    1.7 ± 0.1
    4.9 ± 0.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3562
    Analysis specification
    Pre-specified
    Analysis type
    superiority [49]
    P-value
    < 0.001 [50]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    3.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.9
         upper limit
    3.54
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [49] - If the differences in both primary end points were significant with the use of the Hochberg procedure, a fixed-sequence testing procedure was used for bone mineral density and the key secondary end point of nonvertebral fracture to adjust for multiple comparisons and to maintain an overall significance level of 0.05.
    [50] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density at the Lumbar Spine at Month 36

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density at the Lumbar Spine at Month 36
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.
    End point type
    Secondary
    End point timeframe
    Baseline and month 36
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1597
    1593
    Units: percent change
        least squares mean (standard error)
    7.8 ± 0.2
    15.2 ± 0.2
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3190
    Analysis specification
    Pre-specified
    Analysis type
    superiority [51]
    P-value
    < 0.001 [52]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    7.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    6.84
         upper limit
    7.89
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.3
    Notes
    [51] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [52] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density of the Total Hip at Month 36

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density of the Total Hip at Month 36
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.
    End point type
    Secondary
    End point timeframe
    Baseline and month 36
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1653
    1653
    Units: percent change
        least squares mean (standard error)
    3.5 ± 0.1
    7.2 ± 0.1
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3306
    Analysis specification
    Pre-specified
    Analysis type
    superiority [53]
    P-value
    < 0.001 [54]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    3.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.29
         upper limit
    4.02
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [53] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [54] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction.

    Secondary: Percent Change from Baseline in Bone Mineral Density of the Femoral Neck at Month 36

    Close Top of page
    End point title
    Percent Change from Baseline in Bone Mineral Density of the Femoral Neck at Month 36
    End point description
    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. The analysis was conducted in all randomized participants with a baseline and ≥ 1 post-baseline evaluation during the open-label period at or before month 36; Missing values were imputed by carrying forward the last non-missing post-baseline value in the open-label treatment period prior to the missing value.
    End point type
    Secondary
    End point timeframe
    Baseline and month 36
    End point values
    Alendronate/Alendronate Romosozumab/Alendronate
    Number of subjects analysed
    1653
    1653
    Units: percent change
        least squares mean (standard error)
    2.4 ± 0.2
    6.0 ± 0.2
    Statistical analysis title
    Primary Analysis
    Comparison groups
    Alendronate/Alendronate v Romosozumab/Alendronate
    Number of subjects included in analysis
    3306
    Analysis specification
    Pre-specified
    Analysis type
    superiority [55]
    P-value
    < 0.001 [56]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    3.6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.18
         upper limit
    3.97
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2
    Notes
    [55] - This endpoint was not included in the sequential testing procedure and was analyzed without multiplicity adjustment at a significance level of 0.05 (two-sided).
    [56] - Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    The 12-month double-blind treatment phase and overall study period which includes AEs up to the end of study for subjects who received an open-label dose and up to 12 months for subjects who did not; overall median duration of follow-up was 36 months.
    Adverse event reporting additional description
    The safety analysis set included all randomized subjects who received ≥ 1 active dose of investigational product in the 12-month double-blind alendronate-controlled study period. Two participants randomized to alendronate received romosozumab in error and are counted in the romosozumab group for safety.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    12-Month Double-blind Period: Alendronate 70 mg QW
    Reporting group description
    Participants received 70 mg alendronate once a week (QW) and placebo to romosozumab subcutaneously once a month for 12 months during the double-blind treatment period.

    Reporting group title
    Overall Study: Alendronate / Alendronate
    Reporting group description
    Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.

    Reporting group title
    Overall Study: Romosozumab / Alendronate
    Reporting group description
    Participants received 210 romosozumab mg subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.

    Reporting group title
    12-Month Double-blind Period: Romosozumab 210 mg QM
    Reporting group description
    Participants received 210 mg romosozumab subcutaneously once a month (QM) and placebo to alendronate orally once a week for the first 12 months during the double-blind treatment period.

    Serious adverse events
    12-Month Double-blind Period: Alendronate 70 mg QW Overall Study: Alendronate / Alendronate Overall Study: Romosozumab / Alendronate 12-Month Double-blind Period: Romosozumab 210 mg QM
    Total subjects affected by serious adverse events
         subjects affected / exposed
    278 / 2014 (13.80%)
    638 / 2014 (31.68%)
    611 / 2040 (29.95%)
    262 / 2040 (12.84%)
         number of deaths (all causes)
    22
    103
    101
    30
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Burns third degree
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    Carbon monoxide poisoning
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Clavicle fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Concussion
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Contusion
         subjects affected / exposed
    1 / 2014 (0.05%)
    7 / 2014 (0.35%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 7
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Craniocerebral injury
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Extradural haematoma
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Facial bones fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    4 / 2014 (0.20%)
    11 / 2014 (0.55%)
    13 / 2040 (0.64%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 13
    0 / 15
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femoral neck fracture
         subjects affected / exposed
    12 / 2014 (0.60%)
    31 / 2014 (1.54%)
    15 / 2040 (0.74%)
    5 / 2040 (0.25%)
         occurrences causally related to treatment / all
    0 / 12
    1 / 31
    0 / 16
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 1
    Femur fracture
         subjects affected / exposed
    12 / 2014 (0.60%)
    51 / 2014 (2.53%)
    42 / 2040 (2.06%)
    11 / 2040 (0.54%)
         occurrences causally related to treatment / all
    0 / 12
    2 / 51
    3 / 45
    0 / 11
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Fibula fracture
         subjects affected / exposed
    4 / 2014 (0.20%)
    9 / 2014 (0.45%)
    5 / 2040 (0.25%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 9
    1 / 5
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foot fracture
         subjects affected / exposed
    3 / 2014 (0.15%)
    5 / 2014 (0.25%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 6
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foreign body
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fractured ischium
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fractured sacrum
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal anastomotic leak
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Graft complication
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hand fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Humerus fracture
         subjects affected / exposed
    7 / 2014 (0.35%)
    16 / 2014 (0.79%)
    6 / 2040 (0.29%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 16
    0 / 6
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ilium fracture
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Incisional hernia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Joint injury
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Laceration
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ligament sprain
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Limb injury
         subjects affected / exposed
    2 / 2014 (0.10%)
    3 / 2014 (0.15%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lip injury
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar vertebral fracture
         subjects affected / exposed
    1 / 2014 (0.05%)
    8 / 2014 (0.40%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 8
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meniscus injury
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscle rupture
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Overdose
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Patella fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    5 / 2014 (0.25%)
    6 / 2040 (0.29%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 6
    0 / 6
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post laminectomy syndrome
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural bile leak
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pubis fracture
         subjects affected / exposed
    4 / 2014 (0.20%)
    7 / 2014 (0.35%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 7
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Radius fracture
         subjects affected / exposed
    12 / 2014 (0.60%)
    20 / 2014 (0.99%)
    14 / 2040 (0.69%)
    8 / 2040 (0.39%)
         occurrences causally related to treatment / all
    0 / 12
    0 / 20
    0 / 14
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rib fracture
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Scapula fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skull fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Soft tissue injury
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal compression fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stoma site haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subarachnoid haematoma
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subarachnoid haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    4 / 2040 (0.20%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 5
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural haemorrhage
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thoracic vertebral fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    5 / 2014 (0.25%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 5
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tibia fracture
         subjects affected / exposed
    5 / 2014 (0.25%)
    8 / 2014 (0.40%)
    6 / 2040 (0.29%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 8
    1 / 6
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Toxicity to various agents
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ulna fracture
         subjects affected / exposed
    6 / 2014 (0.30%)
    11 / 2014 (0.55%)
    5 / 2040 (0.25%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 11
    0 / 5
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound dehiscence
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound evisceration
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wrist fracture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carcinoembryonic antigen increased
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coagulation time prolonged
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Creatinine renal clearance decreased
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Heart rate decreased
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Liver function test abnormal
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Medical observation normal
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Weight decreased
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute coronary syndrome
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute left ventricular failure
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    2 / 2014 (0.10%)
    15 / 2014 (0.74%)
    16 / 2040 (0.78%)
    8 / 2040 (0.39%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 19
    0 / 17
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 5
    0 / 5
    0 / 3
    Angina pectoris
         subjects affected / exposed
    3 / 2014 (0.15%)
    6 / 2014 (0.30%)
    7 / 2040 (0.34%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 6
    0 / 7
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    Angina unstable
         subjects affected / exposed
    2 / 2014 (0.10%)
    7 / 2014 (0.35%)
    5 / 2040 (0.25%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 9
    0 / 5
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aortic valve stenosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arrhythmia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arrhythmia supraventricular
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Arteriospasm coronary
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    4 / 2014 (0.20%)
    17 / 2014 (0.84%)
    12 / 2040 (0.59%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 5
    2 / 19
    0 / 15
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    3 / 2014 (0.15%)
    4 / 2014 (0.20%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    1 / 4
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bradyarrhythmia
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Bradycardia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 2
    0 / 0
    Cardiac disorder
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    5 / 2014 (0.25%)
    25 / 2014 (1.24%)
    18 / 2040 (0.88%)
    5 / 2040 (0.25%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 31
    0 / 22
    0 / 5
         deaths causally related to treatment / all
    0 / 1
    0 / 5
    0 / 3
    0 / 2
    Cardiac failure acute
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Cardiac failure chronic
         subjects affected / exposed
    1 / 2014 (0.05%)
    5 / 2014 (0.25%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 6
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    5 / 2014 (0.25%)
    12 / 2014 (0.60%)
    9 / 2040 (0.44%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 15
    0 / 9
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 4
    0 / 2
    0 / 0
    Cardiac tamponade
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Cardiac valve disease
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardio-respiratory arrest
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Cardiogenic shock
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 3
    0 / 0
    Cardiomyopathy
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Cardiopulmonary failure
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 3
    0 / 1
    0 / 1
    Coronary artery disease
         subjects affected / exposed
    0 / 2014 (0.00%)
    5 / 2014 (0.25%)
    3 / 2040 (0.15%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 5
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Coronary artery occlusion
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic cardiomyopathy
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Left ventricular failure
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Mitral valve incompetence
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial fibrosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    3 / 2014 (0.15%)
    8 / 2014 (0.40%)
    8 / 2040 (0.39%)
    5 / 2040 (0.25%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 8
    0 / 8
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    Myocardial ischaemia
         subjects affected / exposed
    1 / 2014 (0.05%)
    4 / 2014 (0.20%)
    6 / 2040 (0.29%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 6
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    Palpitations
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinus bradycardia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinus node dysfunction
         subjects affected / exposed
    1 / 2014 (0.05%)
    5 / 2014 (0.25%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 5
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stress cardiomyopathy
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular extrasystoles
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tachycardia
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tricuspid valve incompetence
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ventricular extrasystoles
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    Blood and lymphatic system disorders
    Anaemia of chronic disease
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    3 / 2014 (0.15%)
    9 / 2014 (0.45%)
    7 / 2040 (0.34%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 10
    0 / 7
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia vitamin B12 deficiency
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhagic anaemia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypochromic anaemia
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Iron deficiency anaemia
         subjects affected / exposed
    2 / 2014 (0.10%)
    4 / 2014 (0.20%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 4
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Microcytic anaemia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Normochromic normocytic anaemia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Splenomegaly
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Altered state of consciousness
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Amnesia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Amyotrophic lateral sclerosis
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aphasia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carotid aneurysm rupture
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carotid arteriosclerosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carpal tunnel syndrome
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carotid artery stenosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    4 / 2040 (0.20%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral arteriosclerosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haematoma
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral ischaemia
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    7 / 2014 (0.35%)
    15 / 2014 (0.74%)
    19 / 2040 (0.93%)
    6 / 2040 (0.29%)
         occurrences causally related to treatment / all
    1 / 8
    1 / 17
    0 / 21
    0 / 6
         deaths causally related to treatment / all
    1 / 2
    1 / 3
    0 / 4
    0 / 1
    Cerebrovascular disorder
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dementia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dementia Alzheimer's type
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    3 / 2014 (0.15%)
    7 / 2014 (0.35%)
    9 / 2040 (0.44%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 10
    0 / 11
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Embolic stroke
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epilepsy
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    5 / 2040 (0.25%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 5
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Essential tremor
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Extrapyramidal disorder
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Facial paralysis
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Generalised tonic-clonic seizure
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Haemorrhagic stroke
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    4 / 2040 (0.20%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 6
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
    Hemiparesis
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydrocephalus
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Hypokinesia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypotonia
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intracranial aneurysm
         subjects affected / exposed
    2 / 2014 (0.10%)
    3 / 2014 (0.15%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Ischaemic cerebral infarction
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    3 / 2040 (0.15%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    Ischaemic neuropathy
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    3 / 2014 (0.15%)
    10 / 2014 (0.50%)
    10 / 2040 (0.49%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 11
    0 / 11
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    Loss of consciousness
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar radiculopathy
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbosacral radiculopathy
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Memory impairment
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mixed dementia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Monoparesis
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Multiple sclerosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Multiple sclerosis relapse
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nerve root compression
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorder
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neuralgia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Optic neuritis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paraesthesia
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paraparesis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paresis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Parkinson's disease
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post-traumatic epilepsy
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Presyncope
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sciatica
         subjects affected / exposed
    2 / 2014 (0.10%)
    3 / 2014 (0.15%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Somnolence
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Speech disorder
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stroke in evolution
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    4 / 2014 (0.20%)
    10 / 2014 (0.50%)
    5 / 2040 (0.25%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 11
    0 / 6
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Toxic encephalopathy
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    2 / 2014 (0.10%)
    5 / 2014 (0.25%)
    11 / 2040 (0.54%)
    6 / 2040 (0.29%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 5
    1 / 11
    1 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular encephalopathy
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vertebrobasilar insufficiency
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Amaurosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cataract
         subjects affected / exposed
    4 / 2014 (0.20%)
    9 / 2014 (0.45%)
    11 / 2040 (0.54%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 10
    2 / 12
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diplopia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocrine ophthalmopathy
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Entropion
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Glaucoma
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Macular fibrosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neovascular age-related macular degeneration
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Retinal artery thrombosis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Retinal detachment
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Retinal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Strabismus
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Visual impairment
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vitreous prolapse
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    5 / 2040 (0.25%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 6
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vertigo positional
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vestibular ataxia
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal adhesions
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal hernia
         subjects affected / exposed
    2 / 2014 (0.10%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    5 / 2040 (0.25%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 5
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    2 / 4
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anal incontinence
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chronic gastritis
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    2 / 2040 (0.10%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis ulcerative
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    3 / 2040 (0.15%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Crohn's disease
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 2014 (0.00%)
    3 / 2014 (0.15%)
    6 / 2040 (0.29%)
    4 / 2040 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 6
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulum
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulum intestinal
         subjects affected / exposed
    2 / 2014 (0.10%)
    3 / 2014 (0.15%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulum intestinal haemorrhagic
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenal polyp
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenal ulcer
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenal ulcer perforation
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspepsia
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    1 / 2
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enteritis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erosive oesophagitis
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femoral hernia
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femoral hernia incarcerated
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Food poisoning
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastric ulcer
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    4 / 2040 (0.20%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 3
    2 / 5
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastric ulcer haemorrhage
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    1 / 2014 (0.05%)
    6 / 2014 (0.30%)
    4 / 2040 (0.20%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 6
    0 / 5
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    6 / 2040 (0.29%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    1 / 6
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal inflammation
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    4 / 2040 (0.20%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhoidal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hiatus hernia
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 2014 (0.05%)
    3 / 2014 (0.15%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    1 / 2014 (0.05%)
    4 / 2014 (0.20%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inguinal hernia strangulated
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    4 / 2040 (0.20%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 4
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Intestinal ulcer
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intra-abdominal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intussusception
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Irritable bowel syndrome
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestinal stenosis
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestinal ulcer
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine polyp
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    2 / 2014 (0.10%)
    2 / 2040 (0.10%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    1 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mechanical ileus
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Melaena
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mesenteric arterial occlusion
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    1 / 2014 (0.05%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstruction gastric
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophageal ulcer
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    1 / 2014 (0.05%)
    2 / 2014 (0.10%)
    2 / 2040 (0.10%)
    2 / 2040 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peptic ulcer
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    3 / 2040 (0.15%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peptic ulcer perforation
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    0 / 2040 (0.00%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Peritoneal adhesions
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peritoneal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    2 / 2040 (0.10%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal prolapse
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    1 / 2040 (0.05%)
    0 / 2040 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Salivary gland calculus
         subjects affected / exposed
    0 / 2014 (0.00%)
    1 / 2014 (0.05%)
    1 / 2040 (0.05%)
    1 / 2040 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 2014 (0.00%)
    0 / 2014 (0.00%)
    5 / 2040 (0.25%)
    3 / 2040 (0.15%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    2 / 5
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0